Plasma amyloid precursor protein is decreased in Alzheimer’s disease

R. N. Martins; J. Muir; W. S. Brooks; H. Creasey; P. Montgomery; P. Sellers; G. A. Broe

Plasma amyloid precursor protein is decreased in Alzheimer’s disease

R. N. Martins^*, J. Muir, W. S. Brooks, H. Creasey, P. Montgomery, P. Sellers, G. A. Broe

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

16 Citations (Scopus)

Abstract

Alzheimer’s disease is characterized by amyloid deposits whose major protein component is βA4. βA4 is a product of the amyloid precursor protein (APP). APP was assayed in partially purified plasma samples from 16 sporadic Alzheimer’s disease patients, 12 age-matched controls, 15 Down’s syndrome individuals aged 19-36 years and 8 young to middle-aged controls (22-51 years). 14 of the 16 Alzheimer’s disease patients had decreased plasma APP when compared with age-matched controls. 14 of the 15 Down’s syndrome individuals had similar levels of APP when compared with age-matched and elderly non-demented controls by immunoblotting, whereas one had levels of APP less than controls. Taken together with results from a previous report (Lancet 1992; 340:453-454), the decreased plasma APP levels mirror the changes observed with cerebrospinal fluid APP levels in Alzheimer’s disease.

Original language	English
Pages (from-to)	757-759
Number of pages	3
Journal	NeuroReport
Volume	4
Issue number	6
Publication status	Published - 1993
Externally published	Yes

Keywords

Alzheimer’s disease
Amyloid precursor protein
Blood plasma
Heparin sepharose
Platelets

Cite this

@article{1cbce485ae244248a2586adff26b11e2,

title = "Plasma amyloid precursor protein is decreased in Alzheimer{\textquoteright}s disease",

abstract = "Alzheimer{\textquoteright}s disease is characterized by amyloid deposits whose major protein component is βA4. βA4 is a product of the amyloid precursor protein (APP). APP was assayed in partially purified plasma samples from 16 sporadic Alzheimer{\textquoteright}s disease patients, 12 age-matched controls, 15 Down{\textquoteright}s syndrome individuals aged 19-36 years and 8 young to middle-aged controls (22-51 years). 14 of the 16 Alzheimer{\textquoteright}s disease patients had decreased plasma APP when compared with age-matched controls. 14 of the 15 Down{\textquoteright}s syndrome individuals had similar levels of APP when compared with age-matched and elderly non-demented controls by immunoblotting, whereas one had levels of APP less than controls. Taken together with results from a previous report (Lancet 1992; 340:453-454), the decreased plasma APP levels mirror the changes observed with cerebrospinal fluid APP levels in Alzheimer{\textquoteright}s disease.",

keywords = "Alzheimer{\textquoteright}s disease, Amyloid precursor protein, Blood plasma, Heparin sepharose, Platelets",

author = "Martins, {R. N.} and J. Muir and Brooks, {W. S.} and H. Creasey and P. Montgomery and P. Sellers and Broe, {G. A.}",

year = "1993",

language = "English",

volume = "4",

pages = "757--759",

journal = "NeuroReport",

issn = "0959-4965",

publisher = "Lippincott Williams & Wilkins",

number = "6",

}

TY - JOUR

T1 - Plasma amyloid precursor protein is decreased in Alzheimer’s disease

AU - Martins, R. N.

AU - Muir, J.

AU - Brooks, W. S.

AU - Creasey, H.

AU - Montgomery, P.

AU - Sellers, P.

AU - Broe, G. A.

PY - 1993

Y1 - 1993

N2 - Alzheimer’s disease is characterized by amyloid deposits whose major protein component is βA4. βA4 is a product of the amyloid precursor protein (APP). APP was assayed in partially purified plasma samples from 16 sporadic Alzheimer’s disease patients, 12 age-matched controls, 15 Down’s syndrome individuals aged 19-36 years and 8 young to middle-aged controls (22-51 years). 14 of the 16 Alzheimer’s disease patients had decreased plasma APP when compared with age-matched controls. 14 of the 15 Down’s syndrome individuals had similar levels of APP when compared with age-matched and elderly non-demented controls by immunoblotting, whereas one had levels of APP less than controls. Taken together with results from a previous report (Lancet 1992; 340:453-454), the decreased plasma APP levels mirror the changes observed with cerebrospinal fluid APP levels in Alzheimer’s disease.

AB - Alzheimer’s disease is characterized by amyloid deposits whose major protein component is βA4. βA4 is a product of the amyloid precursor protein (APP). APP was assayed in partially purified plasma samples from 16 sporadic Alzheimer’s disease patients, 12 age-matched controls, 15 Down’s syndrome individuals aged 19-36 years and 8 young to middle-aged controls (22-51 years). 14 of the 16 Alzheimer’s disease patients had decreased plasma APP when compared with age-matched controls. 14 of the 15 Down’s syndrome individuals had similar levels of APP when compared with age-matched and elderly non-demented controls by immunoblotting, whereas one had levels of APP less than controls. Taken together with results from a previous report (Lancet 1992; 340:453-454), the decreased plasma APP levels mirror the changes observed with cerebrospinal fluid APP levels in Alzheimer’s disease.

KW - Alzheimer’s disease

KW - Amyloid precursor protein

KW - Blood plasma

KW - Heparin sepharose

KW - Platelets

UR - http://www.scopus.com/inward/record.url?scp=0027232985&partnerID=8YFLogxK

M3 - Article

C2 - 8347821

AN - SCOPUS:0027232985

SN - 0959-4965

VL - 4

SP - 757

EP - 759

JO - NeuroReport

JF - NeuroReport

IS - 6

ER -

Plasma amyloid precursor protein is decreased in Alzheimer’s disease

Abstract

Keywords

Other files and links

Fingerprint

Cite this